MMMohammad Ahmed Maher

Mohammad Ahmed Maher

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mohammad Ahmed Maher has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Retracted

    Retracted: Nifedipine alone or combined with sildenafil citrate for management of threatened preterm labour: a randomised trial

    by M.A Maher, T.M Sayyed, S.W El‐Khadry

    Objective: To study the tocolytic action of nifedipine combined with sildenafil citrate (SC) and if the combination is superior to nifedipine alone in inhibiting threatened preterm labour (PTL).Design: Prospective randomised study.Setting: An Egyptian university hospital.Population: Women with threatened PTL who received either nifedipine with SC or nifedipine alone.Methods: Patients were randomly allocated to receive either (1) nifedipine 20 mg orally (stat dose), followed by 10 mg orally every 6–8 hours at the same time as vaginal administration of SC (25 mg at 8‐hourly intervals) or (2) nifedipine alone. Medications were continued for 48–72 hours.Main outcome measures: The percentage of women who remained undelivered during hospitalisation.Results: From January 2015 to November 2016, 239 women were randomised. The baseline characteristics of participants were similar. Nifedipine combined with SC was associated with more women remaining undelivered (81.8 versus 68.6%; P = 0.018) during hospitalisation. Regarding secondary outcomes, the addition of SC was also associated with fewer deliveries within 7 days of admission (9.1 versus 20.3%; P = 0.014), prolonged latency (29 versus 7 days; P = 0.002), fewer admissions to neonatal intensive care units (31.4 versus 44.1%; P = 0.043), fewer very preterm deliveries (from 28 to P = 0.043), and increased neonatal birthweight (1900 versus 1500 g; P = 0.018).Conclusions: Vaginal SC combined with nifedipine is an effective option for tocolytic therapy during threatened PTL.Tweetable Vaginal SC enhances the tocolytic effect of nifedipine.


  • Different analgesics prior to intrauterine device insertion: is there any evidence of efficacy?

    by Mohammad Ahmed Maher

    Response to the letter to the Editor: Which analgesic is efficient prior to intrauterine device insertion? [1]It is our pleasure to see your interest in our published article [2]. You have raised s...


  • Retracted

    RETRACTED ARTICLE: Different analgesics prior to intrauterine device insertion: is there any evidence of efficacy?

    by Nabih I. Elkhouly, Mohammad Ahmed Maher

    Objectives: The aims of this study were to compare three different interventions to reduce pain related to insertion of the intrauterine device (IUD), namely, lidocaine, misoprostol and a non-steroidal anti-inflammatory drug, against a placebo, and to assess the advantages of one drug over another, if any. Methods: This was an open-label randomised placebo-controlled trial of 200 women assigned to receive one of the following medications prior to IUD insertion: 10 ml 1% lidocaine paracervical block, 400 μg oral misoprostol, oral naproxen or placebo tablets. The primary outcome measure was the level of pain experienced at different steps of IUD insertion and 15 min after the procedure, measured by a visual analogue scale (VAS). Results: Between July 2015 and March 2016, 208 women were invited to participate in the study: eight refused and the remaining 200 women were randomised equally into four treatment groups (50 participants in each group). All characteristics were similar between the groups. The mean pain scores recorded during speculum placement, tenaculum application, uterine sounding, IUD insertion and 15 min after insertion were similar among the four groups (p > .05). Adjuvant methods to facilitate insertion, insertion failure or device expulsion were similar between the groups (p > .05). Complications were reported in 17 participants (8.5%); all resolved spontaneously with no further management (p > .05). Conclusion: Despite finding that none of the study drugs seemed effective prior to IUD insertion, insertion did not cause severe pain. The negative findings indicate the need for future research into new strategies to decrease pain during IUD placement.


  • Retracted

    RETRACTED ARTICLE: Different routes and forms of uterotonics for treatment of retained placenta: a randomized clinical trial*

    by Mohammad Ahmed Maher, Tarek Mohammad Sayyed, Nabih Ibrahim Elkhouly

    Objectives: To compare between three different uterotonics (oxytocin, carbetocin and misoprostol) given via three different routes (intraumbilical, intravenous and sublingual, respectively) in reducing the need for manual removal of placenta (MROP). Methods: A randomized trial for cases with retained placenta 30 min following vaginal delivery. They received intraumbilical oxytocin, intravenous carbetocin or sublingual misoprostol. Main outcome measures were delivery of the placenta within 30 min following drug administration, and need for MROP. Secondary outcome measures were injection to placental delivery time, post-delivery hemoglobin, need for blood transfusion or additional uterotonics. Results: The overall success rate was 66.7% (64/96), 71.3% (67/94) and 63.7% (58/91) for oxytocin, carbetocin and misoprostol groups, respectively (p > 0.05). When time needed to achieve placental delivery considered, a significant difference was observed with the shortest time for carbetocin (16.61 ± 3.76 min), then oxytocin (18.28 ± 3.34 min) and lastly misoprostol (23.00 ± 3.38 min) (p p Conclusions: Although we aimed to exploit the advantage of certain drug over another, all seemed to have close efficacy but it would be important that further research should highlight availability, cost, ease of administration and storage requirements to determine which agent would best be used in this clinical scenario.


  • Diagnostic accuracy of ultrasound and MRI in the prenatal diagnosis of placenta accreta

    by Mohammad A. Maher, Ahmed Abdelaziz, Mohamed F. Bazeed

    Objective: To analyze the value of ultrasound followed by magnetic resonance imaging (MRI) in doubtful cases for antenatal detection of placenta accreta.Design: A prospective observational study.Setting: Hospital in the southern region, Saudi Arabia.Sample: Patients with a low‐lying placenta or placenta previa.Methods: The placentas of all included cases were scanned in a systematic fashion using both gray‐scale and color Doppler (transabdominal and transvaginal).Main outcome measures: Explicit ultrasound criteria for placenta accreta were carefully applied, and any case with two or more criteria was labeled as highly suspicious. If only one criterion was detected, then the case was labeled as suspicious and MRI was applied.Results: Five hundred and seventy seven women had a diagnosis of low‐lying placenta or placenta previa. Of these, 42 had placenta accreta confirmed after delivery by pathological examination, and 39 of these were diagnosed prenatally. Ultrasound accurately predicted placenta accreta in 33 of 39 of women and correctly ruled out placenta accreta in 512 of 514 without placenta accreta (sensitivity 95.1% and specificity 95.5%). Twenty (20) women underwent MRI because of suspicion of placenta accreta by ultrasonography. MRI accurately predicted placenta accreta in six of 20 cases and correctly ruled out placenta accreta in 10 of 20 cases (sensitivity 85.7% and specificity 76.9%).Conclusion: Placenta accreta can be successfully detected prenatally using ultrasound. MRI can provide additional information in doubtful cases.


  • Prevention of preterm birth: a randomized trial of vaginal compared with intramuscular progesterone

    by Mohammad Ahmed Maher, Ahmed Abdelaziz, Mohamed Ellaithy, Mohamed Fayez Bazeed

    Objective. To assess efficacy and tolerability of vaginal compared with intramuscular progesterone in reducing the rate of recurrent preterm birth before 34 weeks of gestation. Design. Prospective randomized study. Setting. Obstetrics and Gynecology Department, Armed Forces Hospital Southern Region, Kingdom of Saudi Arabia. Sample. Five‐hundred and eighteen women with a prior history of preterm birth. Methods. Women were randomized to receive either 90 mg of vaginal progesterone gel once daily or 250 mg of intramuscular progesterone weekly. Treatment began between 14 and 18 weeks of gestation and continued until 36 complete weeks of gestation, delivery or the occurrence of premature rupture of membranes. Main outcome measures. The primary outcome measure was delivery before 34 weeks of gestation. The secondary outcome measures were PTB between 34 and 37 weeks of gestation and neonatal outcomes including birthweight, neonatal death, and the need for admission to the neonatal intensive care unit. Results. The baseline characteristics of the study participants were similar. Two‐hundred and thirty‐eight (94.1%) patients in the vaginal group and 226 (90.8%) patients in the intramuscular group were compliant with their medications. Vaginal progesterone was associated with a lower percentage of deliveries before 34 weeks of gestation than the intramuscular preparation (p= 0.02). This association was also observed at 28 and 32 weeks of gestation (p= 0.04). Adverse effects were reported in 14.1% of patients in the intramuscular group, but in only 7.5% of patients in the vaginal group (p= 0.017). Conclusions. Vaginal progesterone was more effective than intramuscular progesterone for the prevention of preterm birth and had fewer adverse effects.